Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers

Khosravi, Alireza; Gharipour, Mojgan; Isfahani, Morteza Abdar; Mohajeri, Hamid; Saadatnia, Mohammad; Roghani, Farshad; Shirani, Shahin; Khaledifar, Arsalan

Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers

Authors

¹ Department of Cardiology, Interventional Cardiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Metabolic syndrome, Molecular Epidemiology, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

³ Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Neuroscience Research Center Hypertension Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁵ Department of Cardiology, School of Medicine, Shahrekord University of Medical Sciences, Isfahan, Iran

Abstract

Background: Identifying factors contributing to the increased risk of deep venous thrombosis (DVT) in each population is vital, because of its life-threatening outcome. The current study aims to find the diagnostic performance of some laboratory coagulation markers for predicting DVT in an Iranian population complaining of DVT in the lower limbs.
Patients and Methods: For this study, 66 consecutive patients with documented DVT, admitted to the Al-Zahra Hospital in Isfahan for the first time, were considered as the case group and 33 patients without DVT documentations were included as the control group. DVT was considered when there was visualization of thrombus or non-compressibility of the vein, confirmed by bilateral lower extremity compression Doppler ultrasonographic examination. Homocysteine, antiphospholipid, and anticardiolipin antibodies were measured in both groups by using sensitive ELISA kits. Protein C was measured via a functional clotting method, and prothrombin was measured by a kinetic, enzymatic assay.
Results: Multivariable analysis showed that the serum homocysteine levels was potentially associated with the presence of DVT after adjusting for age and gender (OR: 1.038, 95% CI: 1.007-1.070, P = 0.017). Comparison of the C statistic showed a partially good discrimination of homocysteine for DVT, with the area under the receiver operating characteristic (ROC) curve being 0.614 and with the optimal cut-off value of 16.5 micromol/L (mmol/L) for men and 14.5 mmol/L for women.
Conclusion: Hyperhomocysteinemia could be considered as an independent risk factor for DVT, with an actual acceptable prognostic value, in the Iran population.

Keywords

References

1.	Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992;152:1660-4.
2.	Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
3.	Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3 ^rd . Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study.Ann Intern Med 2005;143:697-706.
4.	James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005;193:216-9.
5.	Chua K, Kong KH, Chan SP. Prevalence and risk factors of asymptomatic lower extremity deep venous thrombosis in asian neurorehabilitation admissions in Singapore. Arch Phys Med Rehabil 2008;89:2316-23.
6.	Gallus AS, Lee LH, Coghlan DW. New aspects of the blood coagulation cascade, anticoagulants and vein thrombosis in Asia. Ann Acad Med Singapore 2002;31:685-96.
7.	Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326-30.
8.	Riddle DL, Wells PS. Diagnosis of lower-extremity deep vein thrombosis in outpatients. Phys Ther 2004;84:729-35.
9.	Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002;162:747-56.
10.	Kearon C, Ginsberg JS, Douketis J, Crowther M, Brill-Edwards P, Weitz JI, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med 2001;135:108-11.
11.	Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 2000;85:1334-7.
12.	Liu HS, Kho BC, Chan JC, Cheung FM, Lau KY, Choi FP, et al. Venous thromboembolism in the Chinese population-experience in a regional hospital in Hong Kong. Hong Kong Med J 2002;8:400-5.
13.	Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-14.
14.	Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-71.
15.	Motykie GD, Caprini JA, Arcelus JI, Zebala LP, Lee CE, Finke NM, et al. Risk factor assessment in the management of patients with suspected deep venous thrombosis. Int Angiol 2000;19:47-51.
16.	Wilasrusmee C, Kiranantawat K, Horsirimanont S, Lertsithichai P, Reodecha P, Soonthonkit Y, et al. Deep venous thrombosis in surgical intensive care unit: Prevalence and risk factors. Asian J Surg 2009;32:85-8.
17.	Joynt GM, Li TS, Griffith GF, Gomersall CD, Yap FH, Ho AM, et al. The incidence of deep venous thrombosis in Chinese medical Intensive Care Unit patients. Hong Kong Med J 2009;15:24-30.
18.	Anderson FA Jr, Spencer FA. Risk factors forvenous thromboembolism. Circulation 2003;107(23 Suppl 1):I9-16.
19.	Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl3):338S-400S.
20.	Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-71.
21.	Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association.Circulation 1996;93:2212-45.
22.	Ravari H, Zafarghandi MR, Alvandfar D, Saadat S. Serum homocysteine in deep venous thrombosis, peripheral atherosclerosis and healthy Iranians: A case-control study. Pak J Biol Sci 2009;12:1019-24.
23.	Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius study. Arch Intern Med 2000;160:3415-20.
24.	Qiu L, Yan SK, Song YH. Hyperhomocysteinemia and deep-vein thrombosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003;25:706-9.
25.	Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 1996;76:883-6.
26.	Rees MM, Rodgers GM. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59.
27.	Rodgers GM, Kane WH, Pitas RE. Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation. J Clin Invest 1988;81:1911-9.
28.	Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
29.	Blom HJ, Molen EF. Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1994;8(Suppl 2):86-7.
30.	Unlü Y, Kele¸s S, Becit N, Koço ¡g ullari CU, Koçak H, Bakan E. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. Eur J Vasc Endovasc Surg 2005;30:315-8.
31.	Tabrizi A, Bazavar MR, Elmi A, Vahedi A, Dourandish N. Evaluation of molecular genetic variation associated with deep venous thrombosis in lower limb fracturesin traumatic patients. Indian J Med Sci 2012;66:207-13. [PUBMED]
32.	Adimi Naghan P, Malekmohammad M, Jamaati H, Sharifkashani B, Najafi A, Hashemian SM. Venous thromboembolism in medical critically ill patients: Prevalence and incidence. Acta Med Iran2013;51:168-71.
33.	Ueland PM, Refsum H, Brattstrm L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic Cardiovascular Disease, Hemostasis,and Endothelial Function. New York: Marcel Dekker; 1993. p. 183-236.
34.	Castañon MM, Lauricella AM, Kordich L, Quintana I. Plasma homocysteine cutoff values for venous thrombosis. Clin Chem Lab Med 2007;45:232-6.

Advanced Biomedical Research